In glioblastoma, mTOR pathway activation is often driven by genetic alterations, such as mutations in the phosphatidylinositol 3-kinase (PI3K) pathway components, including phosphatase and tensin homolog (PTEN) and epidermal growth factor receptor (EGFR), or other signaling pathways that converge on mTOR. The gene discussed is EGFR; the disease is glioblastoma.